Cellular physical properties in relation to cancer

Information

  • Research Project
  • 6614717
  • ApplicationId
    6614717
  • Core Project Number
    R41CA091386
  • Full Project Number
    3R41CA091386-01S1
  • Serial Number
    91386
  • FOA Number
    PAR-00-061
  • Sub Project Id
  • Project Start Date
    9/20/2001 - 24 years ago
  • Project End Date
    8/31/2003 - 22 years ago
  • Program Officer Name
    WOLPERT, MARY K
  • Budget Start Date
    9/1/2002 - 23 years ago
  • Budget End Date
    8/31/2003 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    S1
  • Award Notice Date
    8/8/2002 - 23 years ago
Organizations

Cellular physical properties in relation to cancer

Animal tumors shrink when treated with anti-vascular/angiogenic (AVA) drugs, or with genetically modified cellular vectors, that cut-off their blood supplies. Clinical implementation of these promising strategies is impeded however, since the cellular factors that influence AVA are not easily measured. To help predict and monitor the AVA potential of candidate therapies, this project will develop an assay for the expression of cellular physical properties that may be involved in AVA behavior. We will focus initially on vascular-related cells, such as endothelial and other types. Several physical properties expressed by endothelial cells are suspected to influence their angiogenic potential, including: (1) adhesion to matrix; (2) cellular deformability; and (3) mechanotransduction processes. Each of these properties is mediated by specific molecules that may be useful targets of AVA therapy and can be assessed with tools that have been used and/or developed by the PI and collaborators. The proposed project will develop flow cytomechanical assay (FCMA; U.S. patent pending), a novel "front end" to standard flow cytometry, that will measure key physical properties relating to angiogenic and tumorigenic potential. During Phase I we will test the system using various cell lines, in combination with genetic manipulations and AVA drugs provided by researchers and commercial suppliers. Endpoint of the project will be proof of the FCMA concept. PROPOSED COMMERCIAL APPLICATIONS: The end product, FCMA, will be a convenient interface to standard cytometers that will be useful for researchers screening potential anti- angiogenic drugs or genetic vectors, and for clinicians to biopsy specimens. FCMA will also have general applicability to cell cytomechanics relating to several other diseases, including cardiovascular. Thus the potential market for the device is large. Patent protection currently pending will be broadened and strengthened by this project.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R41
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    23780
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:23780\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NIAN-CRAE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOMERSET
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    088731713
  • Organization District
    UNITED STATES